CN116211922A - Compound essential oil for aiding sleep and soothing nerves as well as preparation method and application thereof - Google Patents
Compound essential oil for aiding sleep and soothing nerves as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN116211922A CN116211922A CN202211088410.7A CN202211088410A CN116211922A CN 116211922 A CN116211922 A CN 116211922A CN 202211088410 A CN202211088410 A CN 202211088410A CN 116211922 A CN116211922 A CN 116211922A
- Authority
- CN
- China
- Prior art keywords
- essential oil
- parts
- compound
- compound essential
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000341 volatile oil Substances 0.000 title claims abstract description 119
- 150000001875 compounds Chemical class 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 210000005036 nerve Anatomy 0.000 title claims abstract description 10
- 241000207840 Jasminum Species 0.000 claims abstract description 17
- 235000010254 Jasminum officinale Nutrition 0.000 claims abstract description 17
- 241000220317 Rosa Species 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims abstract description 6
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 6
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 229940126680 traditional chinese medicines Drugs 0.000 claims abstract description 3
- 244000223014 Syzygium aromaticum Species 0.000 claims abstract 3
- 230000002936 tranquilizing effect Effects 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 5
- 241000576429 Forsythia suspensa Species 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 229940125725 tranquilizer Drugs 0.000 claims description 4
- 239000003204 tranquilizing agent Substances 0.000 claims description 4
- 239000001273 butane Substances 0.000 claims description 2
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 claims description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 229940079593 drug Drugs 0.000 abstract description 9
- 238000002156 mixing Methods 0.000 abstract description 5
- 241000196324 Embryophyta Species 0.000 abstract description 4
- 241000721047 Danaus plexippus Species 0.000 abstract description 3
- 210000003734 kidney Anatomy 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 14
- 206010022437 insomnia Diseases 0.000 description 14
- 210000002216 heart Anatomy 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 6
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 6
- 230000008451 emotion Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000004620 sleep latency Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 208000019901 Anxiety disease Diseases 0.000 description 4
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 4
- 244000178870 Lavandula angustifolia Species 0.000 description 4
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000000147 hypnotic effect Effects 0.000 description 4
- 239000001102 lavandula vera Substances 0.000 description 4
- 235000018219 lavender Nutrition 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 244000061408 Eugenia caryophyllata Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000000994 depressogenic effect Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 229960001412 pentobarbital Drugs 0.000 description 3
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 3
- 239000000932 sedative agent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- QMVPMAAFGQKVCJ-UHFFFAOYSA-N citronellol Chemical compound OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000003326 hypnotic agent Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 2
- 235000013923 monosodium glutamate Nutrition 0.000 description 2
- 239000004223 monosodium glutamate Substances 0.000 description 2
- 230000003961 neuronal insult Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 229940125723 sedative agent Drugs 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 230000004617 sleep duration Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- QMVPMAAFGQKVCJ-SNVBAGLBSA-N (R)-(+)-citronellol Natural products OCC[C@H](C)CCC=C(C)C QMVPMAAFGQKVCJ-SNVBAGLBSA-N 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 240000008866 Ziziphus nummularia Species 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- JGQFVRIQXUFPAH-UHFFFAOYSA-N beta-citronellol Natural products OCCC(C)CCCC(C)=C JGQFVRIQXUFPAH-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000000484 citronellol Nutrition 0.000 description 1
- 230000002508 compound effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
- A47G—HOUSEHOLD OR TABLE EQUIPMENT
- A47G9/00—Bed-covers; Counterpanes; Travelling rugs; Sleeping rugs; Sleeping bags; Pillows
- A47G9/02—Bed linen; Blankets; Counterpanes
- A47G9/0238—Bed linen
- A47G9/0253—Pillow slips
-
- A—HUMAN NECESSITIES
- A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
- A47G—HOUSEHOLD OR TABLE EQUIPMENT
- A47G9/00—Bed-covers; Counterpanes; Travelling rugs; Sleeping rugs; Sleeping bags; Pillows
- A47G9/02—Bed linen; Blankets; Counterpanes
- A47G9/0238—Bed linen
- A47G9/0261—Blanket or duvet enclosing covers, e.g. bag-like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Anesthesiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a compound essential oil for aiding sleep and soothing nerves, and a preparation method and application thereof. The preparation method comprises the following steps of: butyl essential oil, fructus forsythiae essential oil, rose essential oil and jasmine essential oil. The compound essential oil is prepared by utilizing the compatibility principle of monarch, minister, assistant and guide of traditional Chinese medicines, selecting clove essential oil as monarch drug, weeping forsythiae essential oil as ministerial drug, rose essential oil as assistant and jasmine essential oil as guide, and preparing the compound essential oil for assisting sleep and soothing nerves. The preparation method comprises the step of uniformly mixing the preparation raw materials according to the proportion. The essential oil provided by the invention is prepared by extracting plant essential oil containing natural active ingredients, and has the advantages of abundant raw materials and scientific formula ratio. Experimental study shows that the effects of improving sleep and soothing nerves are remarkable.
Description
Technical Field
The invention belongs to the field of traditional Chinese medicine compositions, and particularly relates to a compound essential oil for aiding sleep and soothing nerves, and a preparation method and application thereof.
Background
In recent years, with the increasing intensity of social competition, people bear pressure caused by various events from psychology and society, and often feel excessive, mood depression and anxiety, and insomnia is caused. Modern researches have shown that the pathogenesis of insomnia mainly comprises dysfunction of HPA axis, reduced GABA expression level, reduced melatonin level and the like. When GABA content level in body is low or GABA function is abnormal, the process of participating in sleep initiation and maintenance is weakened, so that the function of a wake-up bolus is enhanced, the central nervous inhibition effect is weakened, and arousal is induced. The essence of insomnia is considered to be the deficiency and excess of the essence, and is mostly related to viscera dysfunction such as liver, heart, spleen, kidney and the like, heart-mind malnutrition or heart-mind difficulty in tranquilization, and viscera imbalance caused by various reasons is an important factor causing insomnia. Whereas insomnia with disharmony between heart and kidney is common in people, its etiology is that the mind is too much and the emotion is depressed to turn fire. Excessive heart fire can cause downward loss of kidney water, loss of nourishment of kidney yin, and failure of kidney yin to control heart fire. Heart fire can not descend to the kidneys, kidney water can not enter the heart, and heart-kidney coordination is abnormal, so that vexation and insomnia are caused. The therapeutic principle should nourish yin and reduce fire, and transport heart and kidney.
At present, the treatment means aiming at insomnia is mainly drug treatment, namely hypnotic drugs or sedatives are taken. Although hypnotics or sedatives have sedative effects on the central nervous system of the brain, the drugs are short-lived and need to be taken for a long time, which can cause serious side effects on the body. In addition, hypnotics enter the human body through oral administration, enter blood after being digested in stomach, enter the brain through blood circulation, can exert the drug effect, and have great hysteresis in the whole long time.
Aromatic essential oils are volatile materials extracted from aromatic plant processing. Not only has aromatic smell, but also has a unique transnasal delivery way into the brain. Volatile small molecules in the aromatic odor can be absorbed by nasal mucosa tissues and enter the body, and the information is directly transmitted to the brain, so that the emotion and the physiological function of the body are regulated through the limbic system of the brain. Research shows that many essential oils have the effects of improving sleep and soothing nerves, for example, lavender essential oil can shorten the sleep latency of mice and prolong the sleep duration of mice. The compound essential oil provided by the invention can improve insomnia caused by heart-kidney disharmony, is safe in source, quick in absorption, free of side effects, convenient to use and capable of meeting the requirements of users.
Disclosure of Invention
The invention aims to provide compound essential oil with definite effect and capable of improving vexation and insomnia as well as a preparation method and application thereof. The essential oil provided by the invention is prepared by extracting plants containing natural active ingredients, has scientific formula proportion, has obvious sleep-aiding and nerve-soothing effects, and can effectively relieve insomnia symptoms.
The first aspect of the invention discloses compound essential oil for improving vexation and insomnia, which comprises the following preparation raw materials: butyl essential oil, fructus forsythiae essential oil, rose essential oil and jasmine essential oil.
In some embodiments, the preparation materials include the following parts by weight: 1-10 parts of clove essential oil, 1-10 parts of weeping forsythia essential oil, 0.5-5 parts of rose essential oil and 0.5-5 parts of jasmine essential oil.
In some embodiments, the preparation materials include the following parts by weight: 1-5 parts of butane essential oil, 2-6 parts of weeping forsythiae essential oil, 0.5-2 parts of rose essential oil and 0.5-2 parts of jasmine essential oil.
In some embodiments, the preparation materials include the following parts by weight: 4 parts of clove essential oil, 6 parts of weeping forsythia essential oil, 1 part of rose essential oil and 1 part of jasmine essential oil.
The second aspect of the invention provides a preparation method of the compound essential oil, which is characterized in that the preparation raw materials are uniformly mixed.
The third aspect of the invention provides a compound essential oil, which is characterized by being prepared according to the preparation method.
The fourth aspect of the invention provides application of the compound essential oil, which is characterized in that the compound essential oil is used for improving heart-kidney disharmony type insomnia.
The fifth aspect of the invention provides application of the compound essential oil in preparing tranquilization medicines or sanitary products. The method is characterized in that: the tranquillizing medicament is a spray composed of traditional Chinese medicine essential oil, or is a civil sanitary product which is prepared by taking the above essential oil formula as an active ingredient, adding conventional auxiliary materials and according to the conventional preparation process of traditional Chinese medicines, and comprises a pillowcase, a quilt cover and the like.
The sixth aspect of the invention provides a tranquilizer, which is characterized by comprising the compound essential oil. The tranquilizer can also comprise pharmaceutically acceptable auxiliary materials.
Compared with the prior art, the invention has the following technical advantages:
(1) The essential oil provided by the invention is prepared by extracting plant essential oil containing natural active ingredients, and has the advantages of abundant raw materials and scientific formula ratio.
(2) Flos Caryophylli in the compound essential oil is used as a monarch drug for nourishing kidney deficiency, guiding kidney yin upwards and filling heart fire; fructus forsythiae is used as ministerial drug, has the effects of expelling pathogenic cold and cool, clearing heat and purging pathogenic fire, and inducing heart-yang to lower the kidney-water, and can achieve the state of yin-yang balance and water-fire balance; and the rose is added as an adjuvant drug to promote qi circulation and remove depression, and the jasmine regulates qi and harmonizes the middle warmer, so that the qi movement is achieved. The whole formula can nourish yin and reduce fire, traffic heart and kidney, and play a role in helping sleep and tranquillizing.
(3) Experimental study shows that the compound essential oil provided by the invention has a protective effect on PC12 nerve cells damaged by corticosterone, can obviously improve the expression quantity of GABA, and can obviously shorten the sleep latency of mice.
(4) The preparation method is simple, does not need a complex preparation process, and is economical and environment-friendly.
(5) The compound essential oil provided by the invention is safe in source, quick in absorption and remarkable in effect, and can meet the requirements of users.
Drawings
FIG. 1 is a data graph of the effect of compound essential oil on stress-induced neuronal damage;
FIG. 2 is a data graph of the effect of jasmine monosodium glutamate oil on stress-induced neuronal damage;
FIG. 3 is a data graph showing the effect of rose monosodium glutamate on nerve cell damage caused by stress;
FIG. 4 is a graph of data relating to the effect of compound essential oils on GABA expression;
FIG. 5 is a graph showing the effect of compound essential oil on sleep latency in a sleep mouse with a threshold dose of sodium pentobarbital;
compared to the model group, (#P < 0.01);
compared with the control group, the P is less than 0.05, P is less than 0.01, P is less than 0.001.
Detailed Description
The invention is further illustrated by means of the following examples, which are not intended to limit the scope of the invention. The experimental methods, in which specific conditions are not noted in the following examples, were selected according to conventional methods and conditions, or according to the commercial specifications.
Ding Xiangwei it is pungent and warm in nature, enters spleen, stomach, lung and kidney meridians, and Caryophylli flos can warm kidney and strengthen yang, nourish kidney deficiency, induce kidney yin to ascend and perfuse heart fire. Researches show that the clove volatile oil has a stimulation effect on the brain, and can be used for treating insomnia and relieving anxiety and depressed emotion.
Lian Qiao is bitter in flavor and slightly cold in nature, enters lung and heart meridians, and can clear heart heat and treat symptoms such as excessive heart fire, dysphoria with smothery sensation in the chest, palms and soles.
The rose is sweet and slightly bitter in taste, warm in nature, and enters liver and spleen channels, and can sooth liver, promote qi circulation, relieve depression, smooth qi movement and relieve anxiety and depressed emotion. Studies show that citronellol and geraniol in the rose essential oil can increase the sleep duration of mice, and have sedative and hypnotic effects.
Jasmine is pungent and slightly sweet in flavor, warm in nature, and enters liver, spleen and stomach meridians, and can regulate qi, resolve depression and harmonize middle energizer, smooth qi movement, dredge liver qi and improve emotion. Research shows that the jasmine essential oil can improve the central nervous system function and obviously relieve the adverse symptoms such as neurasthenia, insomnia, dreaminess, anxiety, depression and the like.
Example 1
Mixing 5 parts by weight of butyl essential oil, 6 parts by weight of fructus forsythiae essential oil, 1 part by weight of rose essential oil and 1 part by weight of jasmine essential oil, and diluting 1000-2000 parts of 95% ethanol uniformly to obtain the compound essential oil.
Example 2
Mixing 5 parts by weight of butyl essential oil, 6 parts by weight of fructus forsythiae essential oil, 1 part by weight of rose essential oil and 1 part by weight of jasmine essential oil, and diluting with 1000-2000 parts of water to obtain the compound essential oil.
Example 3
Mixing 4 parts by weight of butyl essential oil, 5 parts by weight of fructus forsythiae essential oil, 0.5 part by weight of rose essential oil, 0.5 part by weight of jasmine essential oil, and 1000-2000 parts of 95% ethanol, and uniformly mixing to obtain the compound essential oil.
Example 4
Compound essential oil efficacy test:
(1) The compound essential oil has the protective effect on nerve cell injury caused by stress:
PC12 cells in logarithmic growth phase were collected at a cell density of about 2X 10 4 Individual mL -1 The cell suspension was inoculated in 96-well plates for culture. 37 ℃,5% CO 2 Culturing under the condition for 24 hours, and discarding the original culture medium after the cells adhere to the wall. Cells were divided into control, model and dosing groups. The control group was cultured by adding 100. Mu.L of a medium, and the model group was cultured by adding 100. Mu.L of a medium containing 250. Mu. Mol.L of the final concentration -1 The corticosterone culture medium is cultivated, 100 mu L of culture medium of liquid medicine with different concentrations is respectively added into the administration group, 3 parallel holes are arranged in each group, and MTT detection is carried out.
The experimental results are shown in figures 1-3, the compound essential oil can protect cells when diluted by 10-256 times in the concentration of the original formula, and the drug effect is obvious.
(2) Real-time fluorescent quantitative PCR (RT-qPCR) analysis of the effect of the compound essential oil of the invention on GABA expression:
density of 4×10 5 Individual mL -1 The logarithmic phase of PC12 cell suspension was inoculated at 100. Mu.L per well into 6-well plates and cultured for 24 hours. 2mL of complete medium was added to the control group, and 2mL of 250. Mu. Mol.L was added to the model group -1 Is added with 250 mu mol.L of corticosterone complete culture medium solution -1 2mL of the complete medium solution of corticosterone and the essential oil compositions with different concentrations (the concentration is 1/8, 1/12 and 1/16 of the original composition). After 48h, 1mL of PBS was added to each well and washed 2 times, 1mL of Trizol solution was used to lyse the cells, and the cells were extracted with chloroform and allowed to stand at room temperature for 10min. Centrifuge at 12000rpm at 4℃for 15min. The cell supernatant was aspirated and the RNA sample was precipitated by adding the same volume of isopropanol. Washing with 80% ethanol for 2 times, and volatilizing the residual ethanol. 20. Mu.L of DEPC water was added thereto for solubilization, and quantitative nucleic acid detection was performed. Reverse transcription was performed using PrimeScript II first strand cDNA synthesis kit. The expression level of the gene was quantified using SYBR premix Ex Taq reagent. GAPDH gene expression level was used as an endogenous control, using 2- △△Ct The relative folding changes in gene expression were calculated by the method. The primer sequences are shown in Table 1.
TABLE 1 fluorescent quantitative RT-qPCR primer sequence information
The experimental results are shown in fig. 4, and the compound essential oil can obviously improve the expression quantity of GABA after being diluted by 12-16 times in the original formula.
(3) The influence of the compound essential oil on the sleep latency of a sleeping mouse with a threshold dose of sodium pentobarbital:
kunming mice weighing 18-22g were selected and grouped into 4 groups of 5 mice each. Four days after normal feeding of mice, the experiment was started, the mice were weighed and recorded before the experiment, the first group was a control group, and the mice of the group were perfused with 0.1 mL/kg each day -1 Distilled water and sniffing 1% tween-80 solution for 30min; the second group is semen Ziziphi Spinosae groupGroup mice were perfused with 234 mg/kg daily -1 Semen Ziziphi Spinosae solution, and inhaling 1% tween-80 solution for 30min; the third group is lavender essential oil group, and the mice in the group are irrigated with 0.1 mL/kg of stomach every day -1 Distilled water and sniff 2 mg.kg -1 Lavender essential oil for 30min; the fourth group is compound essential oil group, and the mice in the group are perfused with 0.1 mL/kg of stomach every day -1 Distilled water and sniff 2 mg.kg -1 The compound essential oil is administered for 30min for 7 days. After the end of the last 1 day of administration, 45 mg/kg was intraperitoneally injected into each group of mice -1 Sodium pentobarbital solution, after injection, mice were placed individually in a feeder box and the feeder box was numbered, and the moment at which the specular reflection disappeared for 1min was recorded for each mouse.
As shown in fig. 5, compared with a control group, the administration group can obviously shorten the sleep latency of mice, and in the administration group, the compound essential oil group obtained by the technical scheme of the application is shorter than the wild jujube seed group and the lavender essential oil group, so that the essential oil component in the compound essential oil group has a compound effect, and has better sleep-aiding and nerve-soothing effects compared with a single essential oil component.
The embodiments of the present invention have been described in detail above with reference to the accompanying drawings, but the present invention is not limited to the described embodiments. It will be apparent to those skilled in the art that various changes, modifications, substitutions and alterations can be made to these embodiments without departing from the principles and spirit of the invention, and yet fall within the scope of the invention.
Claims (10)
1. The compound essential oil for aiding sleep and soothing nerves is characterized by comprising the following preparation raw materials: butyl essential oil, fructus forsythiae essential oil, rose essential oil and jasmine essential oil.
2. The compound essential oil for aiding sleep and soothing nerves is characterized by comprising the following preparation raw materials: 1-10 parts of clove essential oil, 1-10 parts of weeping forsythia essential oil, 0.5-5 parts of rose essential oil and 0.5-5 parts of jasmine essential oil.
3. The compound essential oil of claim 1, wherein the compound essential oil comprises the following preparation raw materials in parts by weight: 1-5 parts of butane essential oil, 2-6 parts of weeping forsythiae essential oil, 0.5-2 parts of rose essential oil and 0.5-2 parts of jasmine essential oil.
4. The compound essential oil of claim 1, wherein the compound essential oil comprises the following preparation raw materials in parts by weight: 4 parts of clove essential oil, 6 parts of weeping forsythia essential oil, 1 part of rose essential oil and 1 part of jasmine essential oil.
5. A method for preparing the compound essential oil according to any one of claims 1 to 4, wherein the preparation raw materials are uniformly mixed.
6. A compound essential oil, characterized by being prepared according to the method of claim 5.
7. The use of a compound essential oil according to any one of claims 1-4 or 6, wherein the compound essential oil is used for aiding sleep and soothing the nerves.
8. Use of an essential oil formulation according to any of claims 1-4 or 6 for the preparation of tranquillizing medicaments or hygiene products, characterized in that: the tranquillizing medicament is a spray composed of traditional Chinese medicine essential oil, or is a civil sanitary product which is prepared by taking the above essential oil formula as an active ingredient, adding conventional auxiliary materials and according to the conventional preparation process of traditional Chinese medicines, and comprises a pillowcase and a quilt cover.
9. A tranquilizer comprising a compound essential oil according to any one of claims 1-4 or 6.
10. The tranquilizer of claim 9, further comprising a pharmaceutically acceptable excipient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211088410.7A CN116211922B (en) | 2022-09-07 | 2022-09-07 | Compound essential oil for aiding sleep and soothing nerves as well as preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211088410.7A CN116211922B (en) | 2022-09-07 | 2022-09-07 | Compound essential oil for aiding sleep and soothing nerves as well as preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116211922A true CN116211922A (en) | 2023-06-06 |
CN116211922B CN116211922B (en) | 2024-05-17 |
Family
ID=86583038
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211088410.7A Active CN116211922B (en) | 2022-09-07 | 2022-09-07 | Compound essential oil for aiding sleep and soothing nerves as well as preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116211922B (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1500477A (en) * | 2002-11-13 | 2004-06-02 | 丛繁滋 | Quick result aerosol with plant aroma and its preparation |
-
2022
- 2022-09-07 CN CN202211088410.7A patent/CN116211922B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1500477A (en) * | 2002-11-13 | 2004-06-02 | 丛繁滋 | Quick result aerosol with plant aroma and its preparation |
Also Published As
Publication number | Publication date |
---|---|
CN116211922B (en) | 2024-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100350925C (en) | Novel snuff aerosol | |
US6063383A (en) | Pharmaceutical suppository composites for fever and influenza and method of producing the composites | |
CN105288024B (en) | Medicinal incense with tranquilizing effect and preparation method thereof | |
CN109329609A (en) | One kind containing mint flavored composite essential oil and feed addictive and application | |
CN107569616A (en) | A kind of compound oil for improving sleep and preparation method thereof | |
CN105920476B (en) | Traditional Chinese medicine composition for preventing and treating Alzheimer disease and preparation method thereof | |
CN104688720A (en) | Application of chlorogenic acid in preparation of medicine for treating melanoma and medicine for treating melanoma | |
CN108785357A (en) | A kind of masticinic acid and myrrh terpene compatible composition and its preparation method and application | |
CN106728132A (en) | A kind of medicine of sleep for adjusting insomnia crowd and preparation method thereof | |
CN107468683B (en) | Application of alantolactone and derivatives thereof in preparation of medicines for preventing and treating fatty liver injury | |
CN109793870A (en) | A kind of pure plant essence perfume with antidepression antianxiety | |
CN116211922B (en) | Compound essential oil for aiding sleep and soothing nerves as well as preparation method and application thereof | |
CN110624029A (en) | Traditional Chinese medicine composition for resolving depression, calming heart and soothing nerves and preparation method of external patch | |
CN105213541B (en) | Improve the Rose compound essential oil and preparation method thereof of insomnia due to pressure | |
KR20180083782A (en) | Cosmetic composition comprising withania somnifera, morus australis and pure tea extracts | |
CN112791140A (en) | Composition and application thereof in protecting liver and reducing blood fat | |
CN108404044B (en) | Compound plant incense essential oil for treating depression | |
CN112237604A (en) | Traditional Chinese medicine incense for reducing epidemic infection and preparation process thereof | |
CN100348259C (en) | Medicine composition for raising immunity and its prepn and application | |
CN114984121B (en) | A Chinese medicinal composition with effects of refreshing and relieving fatigue, and its preparation method and application | |
CN116459305A (en) | Compound essential oil for aiding sleep and soothing nerves as well as preparation method and application thereof | |
CN116459323B (en) | Essential oil composition for dysosmia and application thereof | |
CN116019860B (en) | Compound essential oil with effects of inducing resuscitation and refreshing mind and preparation method and application thereof | |
RU2576238C1 (en) | Herbal tea for treating functional disorders of the gall bladder at hypertonic-hyperkinetic type of dyskinesia | |
CN108079059A (en) | A kind of styrax compound essential oil for improvement sleep |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |